Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src

Despite the development of new antineoplastic agents for the treatment of colorectal cancer (CRC), oxaliplatin and fluoropyrimidines remain the most commonly employed drugs for the treatment of both early and advanced disease. Intrinsic or acquired resistance is, however, an important limitation to...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez, Marco, Lucena-Cacace, Antonio, Marín-Gómez, Luis Miguel, Padillo-Ruiz, Javier, Robles-Frias, Maria Jose, Saez, Carmen, Garcia-Carbonero, Rocio, Carnero, Amancio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078079/
https://www.ncbi.nlm.nih.gov/pubmed/27105527
http://dx.doi.org/10.18632/oncotarget.8880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078079/
https://www.ncbi.nlm.nih.gov/pubmed/27105527
http://dx.doi.org/10.18632/oncotarget.8880

Ejemplares similares